<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Extracellular cystatin F is internalised by cytotoxic T lymphocytes and decreases their cytotoxicity</dc:title><dc:creator>Prunk,	Mateja	(Avtor)
	</dc:creator><dc:creator>Perišić Nanut,	Milica	(Avtor)
	</dc:creator><dc:creator>Jakoš,	Tanja	(Avtor)
	</dc:creator><dc:creator>Sabotič,	Jerica	(Avtor)
	</dc:creator><dc:creator>Švajger,	Urban	(Avtor)
	</dc:creator><dc:creator>Kos,	Janko	(Avtor)
	</dc:creator><dc:subject>cystatin F</dc:subject><dc:subject>cathepsins</dc:subject><dc:subject>cytotoxic lymphocytes</dc:subject><dc:subject>granzymes</dc:subject><dc:subject>perforin</dc:subject><dc:subject>TALL-104</dc:subject><dc:description>Cystatin F is a protein inhibitor of cysteine cathepsins, peptidases involved in the activation of the effector molecules of the perforin/granzyme pathway. Cystatin F was previously shown to regulate natural killer cell cytotoxicity. Here, we show that extracellular cystatin F has a role in regulating the killing efficiency of cytotoxic T lymphocytes (CTLs). Extracellular cystatin F was internalised into TALL-104 cells, a cytotoxic T cell line, and decreased their cathepsin C and H activity. Correspondingly, granzyme A and B activity was also decreased and, most importantly, the killing efficiency of TALL-104 cells as well as primary human CTLs was reduced. The N-terminally truncated form of cystatin F, which can directly inhibit cathepsin C (unlike the full-length form), was more effective than the full-length inhibitor. Furthermore, cystatin F decreased cathepsin L activity, which, however, did not affect perforin processing. Cystatin F derived from K-562 target cells could also decrease the cytotoxicity of TALL-104 cells. These results clearly show that, by inhibiting cysteine cathepsin proteolytic activity, extracellular cystatin F can decrease the cytotoxicity of CTLs and thus compromise their function.</dc:description><dc:date>2020</dc:date><dc:date>2022-02-04 12:59:12</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>134854</dc:identifier><dc:identifier>UDK: 616.1</dc:identifier><dc:identifier>ISSN pri članku: 2072-6694</dc:identifier><dc:identifier>DOI: 10.3390/cancers12123660</dc:identifier><dc:identifier>COBISS_ID: 43955203</dc:identifier><dc:language>sl</dc:language></metadata>
